Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Lactobacillus reuteri DSM 17938 and Reduced Duration of Diarrhea

Research synthesisModerate evidenceMixed effect size5 studies · 5 beneficial · 0 neutral · 0 harmful

Across 5 studies, all reported beneficial effects of Lactobacillus reuteri DSM 17938 on reducing diarrhea duration, with effect sizes ranging from small to large (predominantly moderate-to-large). Statistically significant findings were observed in 4 out of 5 studies. The most-studied dose was approximately 1-2 × 10^8 CFU/day, primarily in children with acute diarrhea or at risk for antibiotic-associated diarrhea.

  • Effective dose range: 1 × 10^8 to 2 × 10^8 CFU/day
  • Studied populations: Children (including those with acute diarrhea, acute otitis media/rhinosinusitis, and healthy children attending day care centers)

Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). The evidence base is small (only 5 studies), and one study was a narrative review with no sample size or significance data. Effect sizes varied considerably (small to large), and study durations were not consistently reported.

Generated May 22, 2026
Doses used in studies
  • CFU/day: 100 million–2 billion (median 150 million, IQR 100 million650 million) 4 studies
  • CFU single-dose: 100 million (median 100 million, IQR 100 million100 million) 1 study
Safety in these studies
5 of 5 papers
Back to top